News & Updates
Filter by Specialty:
Post-ICH antiplatelet therapy not linked to recurrent ICH
Initiating antiplatelet therapy following an intracerebral haemorrhage (ICH) that occurred during antithrombotic use does not lead to recurrent symptomatic ICH, according to extended results of the RESTART* trial.
Post-ICH antiplatelet therapy not linked to recurrent ICH
28 Oct 2021
ULTIMATE: Biologic DMARD affords inflammation control in psoriatic arthritis
Interleukin-17 inhibition with the biologic disease-modifying antirheumatic drug (DMARD) secukinumab appears to produce a substantial reduction in synovitis in psoriatic arthritis, in addition to improvements in the signs and symptoms of the disease, according to the results of the phase III ULTIMATE.
ULTIMATE: Biologic DMARD affords inflammation control in psoriatic arthritis
28 Oct 2021
Modified dual therapy on par with recommended regimen in H. pylori infection
A modified dual therapy as first-line treatment for H. pylori infection demonstrates equal efficacy and compliance relative to recommended regimens, reveals a study. Moreover, a generally modified dual therapy has fewer side effects.
Modified dual therapy on par with recommended regimen in H. pylori infection
28 Oct 2021
Adjuvant atezolizumab improves DFS in early-stage NSCLC
In patients with completely resected stage II–IIIA non-small-cell lung cancer (NSCLC) who had previously received adjuvant cisplatin chemotherapy, adjuvant atezolizumab extended disease-free survival (DFS), particularly in those with PD-L1 expression ≥1 percent on tumour cells, interim results of the phase III IMpower010 trial showed.
